HCPLive
American Psychiatric Association 167th Annual Meeting

American Psychiatric Association 167th Annual Meeting | APA 2014

The American Psychiatric Association annual meeting "will feature a variety of innovative sessions and inspiring courses with tracks focusing on changing the practice and perception of psychiatry."

Conference Coverages

Paliperidone Palmitate Delays Relapse in Patients with Schizoaffective Disorder
Paliperidone Palmitate Delays Relapse in Patients with Schizoaffective Disorder
Patients with schizoaffective disorder who were treated with paliperidone palmitate (as monotherapy and adjunctive therapy) experienced delayed time to relapse and reduced risk of relapse compared to patients treated with placebo.
ADHD Drug Also Produces Promising Results in Adults with Binge Eating Disorder
Adult patients with binge eating disorder who were treated for 12 weeks with lisdexamfetamine dimesylate reported having 4 fewer binge days per week, and also experienced improvements in weight and triglyceride levels.
Bremelanotide Treatment Improves Sexual Function and Reduces Associated Distress Levels in Women
Patients in a trial of a first-in-class medication for the treatment of female sexual dysfunction reported improvement in overall sexual function, including an increase in the number of satisfying sexual events, and a concomitant decrease in distress levels associated with sexual dysfunction.
Smaller Dose of Vilazodone Safe and Effective for Major Depressive Disorder
Study results presented at the 2014 annual meeting of the American Psychiatric Association show that a reduced dosage of the antidepressant vilazodone is as effective as the currently approved dosage.
Vortioxetine May Also Improve Cognition in Adult Patients with Major Depressive Disorder
Study results presented at the 2014 APA annual meeting show patients treated with vortioxetine significant improvement in composite cognition scores compared to patients treated with placebo, independent of the drug’s effect on their depression symptoms.
Brexpiprazole Shown to Be Effective for Major Depressive Disorder with Fewer Side Effects Than Aripiprazole
Results from a six-week study show patients with major depressive disorder treated with brexpiprazole had significantly reduced risk of akathisia and other side effects.
Botox Injection Associated with Significant, Sustained Improvement in Symptoms of Major Depressive Disorder
By paralyzing the facial muscles involved in producing frown lines, onabotulinumtoxinA injection seems to alleviate depression, especially among patients who exhibit a high degree of hyperactivity.

Most Popular

$vacMongoViewPlus$ $vAR$